Loading…
iBio, Inc. is projected to rise to $1.52 by 2027, a +9% move from its current price of $1.40. IBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.36 | $1.40 | $1.44 | -0.02% |
| Aug 6 | $1.35 | $1.40 | $1.45 | -0.04% |
| Aug 7 | $1.34 | $1.40 | $1.47 | -0.05% |
| Aug 8 | $1.33 | $1.40 | $1.48 | -0.07% |
| Aug 9 | $1.32 | $1.40 | $1.48 | -0.09% |
| Aug 10 | $1.31 | $1.40 | $1.49 | -0.11% |
| Aug 11 | $1.30 | $1.40 | $1.50 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.30 | $1.40 | $1.50 | -0.13% |
| Week 2 | $1.26 | $1.40 | $1.54 | -0.26% |
| Week 3 | $1.23 | $1.39 | $1.58 | -0.38% |
| Week 4 | $1.21 | $1.39 | $1.60 | -0.51% |
| Week 5 | $1.19 | $1.39 | $1.63 | -0.64% |
| Week 6 | $1.17 | $1.39 | $1.65 | -0.76% |
| Week 7 | $1.15 | $1.39 | $1.67 | -0.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
iBio, Inc. is a preclinical stage biotechnology company that develops AI antibody solutions for the cardiometabolic and obesity space. Its technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Its product pipelines for the cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhances the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2 expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases.
The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
iBio, Inc. (IBIO) is the asset trading at $1.45, with a market cap of $72.03M and a rank of 4190. The current price sits within a landscape of a neutral near-term outlook, while the longer-term forecast points to meaningful upside.
Forecasted 2026 average price is $1.45 and 2050 average price is $6.00, with the potential for substantial appreciation into later years. The forecast also shows rising confidence over time, with the long-horizon ROI expanding to 313.8 by 2050. Annualized volatility is high at 50%, underscoring the expected price swings in this equity.
A major floor 21.4% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 25.0% above — a clean break opens room to run.
A major ceiling 60.0% above — clearing it would confirm fresh momentum.
Key IBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.40 | Buy | $1.40 | Buy |
| MA 10 | $1.40 | Buy | $1.41 | Sell |
| MA 20 | $1.44 | Sell | $1.45 | Sell |
| MA 50 | $1.62 | Sell | $1.58 | Sell |
| MA 100 | $1.78 | Sell | $1.70 | Sell |
| MA 200 | $1.82 | Sell | $1.77 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.94 | Neutral |
| Stoch RSI (14) | 85.08 | Sell |
| CCI (20) | -44.98 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -2.10 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 48.73 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 1.38 | Buy |
| ADX (14) | 21.47 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is neutral. RSI 14 is 40, indicating modest momentum. The stock trades around the SMA50 of $1.63 and below the SMA200 of $1.81, suggesting near-term balance around the moving-averages. Key levels to watch are support at $1.35 and resistance at $1.75, with a 30-day price range of $1.21 to $1.73.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.35 | $1.40 | $1.78 | 0% | Neutral | |
| $1.22 | $1.52 | $2.01 | +9% | Neutral | |
| $1.37 | $1.77 | $2.42 | +26% | Bullish | |
| $1.50 | $1.97 | $2.77 | +40% | Bullish | |
| $1.58 | $2.12 | $3.06 | +51% | Bullish | |
| $1.55 | $2.12 | $3.13 | +51% | Bullish | |
| $1.53 | $2.12 | $3.19 | +52% | Bullish | |
| $1.58 | $2.23 | $3.42 | +60% | Bullish | |
| $1.71 | $2.45 | $3.81 | +75% | Bullish | |
| $2.05 | $2.98 | $4.70 | +113% | Bullish | |
| $2.30 | $3.57 | $5.98 | +155% | Bullish | |
| $3.58 | $6.20 | $11.35 | +343% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.35 | $1.40 | $1.69 | +0.00% |
| September 2026 | $1.20 | $1.42 | $1.72 | +1.45% |
| October 2026 | $1.16 | $1.38 | $1.69 | -3.06% |
| November 2026 | $1.14 | $1.37 | $1.69 | -0.71% |
| December 2026 | $1.19 | $1.43 | $1.78 | +4.57% |
Click any year to see its month-by-month IBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IBIO price prediction for 2026 points to an average of $1.40 (low $1.35, high $1.78) — a potential gain of 0% on today's $1.40. Price action looks broadly range-bound.
In 2027, IBIO is projected to trade between $1.22 and $2.01, averaging $1.52 — a potential gain of +9% from today's $1.40. That is up +9% on the projected 2026 average. A consolidation phase looks the most probable path here.
iBio, Inc.'s 2028 outlook centres on $1.77, within a $1.37 to $2.42 range. That is up +16% on the projected 2027 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2029, IBIO could reach as high as $2.77, with a base case around $1.97 and support toward $1.50 — roughly +40% from $1.40. Buyers look set to stay in control over this stretch.
Expect IBIO to range from $1.58 to $3.06 through 2030. The $2.12 average target implies a +51% move from current prices. That is up +8% on the projected 2029 average. Momentum favours further upside here.
The IBIO price prediction for 2031 points to an average of $2.12 (low $1.55, high $3.13) — a potential gain of +51% on today's $1.40. Buyers look set to stay in control over this stretch.
In 2032, IBIO is projected to trade between $1.53 and $3.19, averaging $2.12 — a potential gain of +52% from today's $1.40. That is up 0% on the projected 2031 average. Momentum favours further upside here.
iBio, Inc.'s 2033 outlook centres on $2.23, within a $1.58 to $3.42 range. That is up +5% on the projected 2032 average. That marks a +60% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IBIO could reach as high as $3.81, with a base case around $2.45 and support toward $1.71 — roughly +75% from $1.40. Momentum favours further upside here.
Expect IBIO to range from $2.05 to $4.70 through 2035. The $2.98 average target implies a +113% move from current prices. That is up +22% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IBIO price prediction for 2040 points to an average of $3.57 (low $2.30, high $5.98) — a potential gain of +155% on today's $1.40. Momentum favours further upside here.
In 2050, IBIO is projected to trade between $3.58 and $11.35, averaging $6.20 — a potential gain of +343% from today's $1.40. That is up +74% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IBIO today (≈ 714.285714 IBIO) could be worth
$4,430.72
+$3,430.72 (+343%) by 2050 · US Dollar
Based on the average projected IBIO price of $6.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IBIOwould be worth at today's price.
$1,000 invested in IBIO on Jul 31, 2025 (≈ 1,470.58822 IBIO) would be worth
$2,058.82
+$1,058.82 (+105.9%) today · 2.06× · US Dollar
Based on a IBIO entry price of $0.68 vs. today's $1.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.43 | $979.02 | -2.1% |
| 1 month ago | $1.75 | $800 | -20.0% |
| 3 months ago | $1.59 | $880.5 | -11.9% |
| 6 months ago | $2.3 | $608.7 | -39.1% |
| 1 year ago | $0.68 | $2,058.82 | +105.9% |
| All time (5.0y) ago | $630 | $2.22 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IBIO forecast.
Our base-case forecast reaches $2.80 around 2035.
Implied market cap at $2.80: $139.1M
The multi-year forecast indicates a bullish trajectory with rising average prices and substantial upside over time. By 2030, the average price is projected at $2.11 with a 45.8 ROI. By 2040, the average price is projected at $3.45 with a 137.9 ROI.
By 2050, the average price is projected at $6.00 with a 313.8 ROI. The outlook remains bullish through the 2030s and 2040s, with higher price targets and continued gains reflected in the forecast. While sentiment improves in later years, these are estimates, not guarantees, and volatility remains a meaningful risk given the 50% annualized volatility and the nature of a preclinical-stage biotech stock.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.11 with a range from $1.57 to $3.06 and a 45.8 ROI.
The forecast presents a path of rising averages from 2026 ($1.45 average) to 2050 ($6.00 average) with increasing ROI, culminating at 313.8 by 2050. These are estimates, not guarantees, and reflect potential upside alongside significant risk.
The 2040 forecast targets an average price of $3.45 with a maximum around $5.80, indicating the possibility of testing or exceeding $5 on the upside within that horizon.
The current price is $1.45 and the market cap is $72.03M.
The 2050 forecast lists an average price of $6.00 with a minimum of $3.44 and a maximum of $11.02, and a ROI of 313.8, with sentiment rated as BULLISH.
iBio, Inc. Community Discussion
0Share your iBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.